Inequalities in secondary prevention pathways after ischaemic heart disease: a cohort study
Abstract
Background: Socioeconomic inequalities in outcomes after ischaemic heart disease are well documented, yet less is known about how these inequalities manifest across the full pathway of secondary prevention, particularly during the transition from hospital to primary care.
Methods: We conducted a nationwide population-based cohort study including 93,159 individuals hospitalised with ischaemic heart disease in Denmark (2016–2022). Secondary prevention was assessed across three key components: cardiac rehabilitation, preventive medication (antiplatelet or statin therapy), and annual general practice follow-up. A composite indicator captured receipt of all three components. Relative risks (RR) were estimated using modified Poisson regression, adjusted for demographic and clinical factors. Socioeconomic position was measured using education, income, cohabitation, and workforce status.
Results: Cardiac rehabilitation uptake was 41.2%, with 73.7% adherence among participants. Preventive medication was widely used (antiplatelet: 86.1%; statins: 77.0%), while 56.0% attended general practice follow-up. Only 25.9% received all three components, and 7.6% received none. Lower socioeconomic position was consistently associated with reduced likelihood of comprehensive secondary prevention, particularly among individuals with low income (RR 0.70, 95% CI 0.67–0.73), those living alone (RR 0.77, 0.75–0.79), and those unemployed (RR 0.82, 0.75–0.89). Inequalities were most pronounced for cardiac rehabilitation uptake and persisted over time.
Conclusions: Substantial socioeconomic inequalities persist across the full pathway of secondary prevention after ischaemic heart disease, even within a universal healthcare system. These inequalities accumulate across care components and highlight critical gaps at the transition from hospital to community care.
Key messages: • Inequalities in secondary prevention after ischaemic heart disease extend beyond single interventions and accumulate across care pathways.
• Equity-oriented, cross-sectoral strategies targeting care transitions are needed to improve uptake and continuity of preventive care after ischaemic heart disease.
Related
- Evaluating the quality and safety of a nurse practitioner-led virtual clinic for secondary prevention in stable coronary artery disease: a pilot feasibility study.
- Effects of minocycline on health-related quality of life in patients with acute ischaemic stroke in China: a prespecified secondary analysis of the EMPHASIS trial
- Trends and Factors Associated with LDL-C Treatment Target Attainment Rates among Patients with Secondary Prevention Setting of Atherosclerotic Cardiovascular Disease: Assessments from Japanese Health Checkup Data
- Trends, cross-country inequalities and risk factors in the global burden of chronic obstructive pulmonary disease mortality, 1990-2021: a secondary data analysis of the Global Burden of Disease Study 2021.
- Near infrared spectroscopy during non-ischaemic handgrip exercise reveals divergent muscle oxygenation signatures in mitochondrial disease and sarcopenia
BibTeX
@article{maribo2026inequalities,
title = {{Inequalities in secondary prevention pathways after ischaemic heart disease: a cohort study}},
author = {T Maribo and J Refsgaard and B Christensen and S Palner and V Lynggaard and ML Svendsen},
journal = {The European Journal of Public Health},
year = {2026},
month = oct,
doi = {10.1093/eurpub/ckag169.497},
url = {https://doi.org/10.1093/eurpub/ckag169.497},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Inequalities in secondary prevention pathways after ischaemic heart disease: a cohort study
AU - T Maribo
AU - J Refsgaard
AU - B Christensen
AU - S Palner
AU - V Lynggaard
AU - ML Svendsen
PY - 2026
DA - 2026/10/01
JO - The European Journal of Public Health
DO - 10.1093/eurpub/ckag169.497
UR - https://doi.org/10.1093/eurpub/ckag169.497
AB - Background: Socioeconomic inequalities in outcomes after ischaemic heart disease are well documented, yet less is known about how these inequalities manifest across the full pathway of secondary prevention, particularly during the transition from hospital to primary care. Methods: We conducted a nationwide population-based cohort study including 93,159 individuals hospitalised with ischaemic heart disease in Denmark (2016–2022). Secondary prevention was assessed across three key components: cardiac rehabilitation, preventive medication (antiplatelet or statin therapy), and annual general practice follow-up. A composite indicator captured receipt of all three components. Relative risks (RR) were estimated using modified Poisson regression, adjusted for demographic and clinical factors. Socioeconomic position was measured using education, income, cohabitation, and workforce status. Results: Cardiac rehabilitation uptake was 41.2%, with 73.7% adherence among participants. Preventive medication was widely used (antiplatelet: 86.1%; statins: 77.0%), while 56.0% attended general practice follow-up. Only 25.9% received all three components, and 7.6% received none. Lower socioeconomic position was consistently associated with reduced likelihood of comprehensive secondary prevention, particularly among individuals with low income (RR 0.70, 95% CI 0.67–0.73), those living alone (RR 0.77, 0.75–0.79), and those unemployed (RR 0.82, 0.75–0.89). Inequalities were most pronounced for cardiac rehabilitation uptake and persisted over time. Conclusions: Substantial socioeconomic inequalities persist across the full pathway of secondary prevention after ischaemic heart disease, even within a universal healthcare system. These inequalities accumulate across care components and highlight critical gaps at the transition from hospital to community care. Key messages: • Inequalities in secondary prevention after ischaemic heart disease extend beyond single interventions and accumulate across care pathways. • Equity-oriented, cross-sectoral strategies targeting care transitions are needed to improve uptake and continuity of preventive care after ischaemic heart disease.
SN - 1101-1262
SN - 1464-360X
ER -